theMednetRegister

Hepatology   

Questions discussed in this category

What is your approach to liver transplantation candidacy in those with decompensated cirrhosis who have been treated for a solid-organ malignancy, such as oral SCC?
Is there a minimum time of waiting that is necessary between the completion of cancer treatment and liver transplantation?
1 Answer available
How do you counsel patients on the risks vs benefits of naltrexone for alcohol use disorder with persistently elevated liver enzymes?
Is there an absolute cutoff for AST/ALT that you use where the risks outweigh the potential harm reduction benefits of using the medication? &nbs...
2 Answers available
In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?
If you prefer monitoring strategy, how frequently do you repeat labs and what is your referral thresholds to hepatology if you're practicing in primar...
1 Answer available
How do you decide when to use acid-suppressive medications for GI prophylaxis when patients are on prolonged corticosteroid therapy?
Do you prescribe it universally or based on specific risk factors?
2 Answers available
What are your top takeaways from AASLD 2025?
1 Answer available
Should an individual who received the purified protein Hepatitis B vaccine in 1985 receive a booster or have antibody titers checked?
1 Answer available
How would you approach the management of asymptomatic ALT and GGT elevation in an older adult patient with depression with psychosis and without history of hepatitis who recently had dose of quetiapine increased and new initiation of SNRI?
1 Answer available
How do you decide between anticoagulation or portal vein recanalization in a patient with portal vein thrombosis?
Is this a sequential process? Simultaneous? 
1 Answer available
How do you manage symptomatic ascites in a patient with SBP?
At what point do you feel comfortable using diuretics or performing a therapeutic paracentesis?
3 Answers available
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
2 Answers available
For cirrhotic patients that we take care of in the community, when should be the optimal timing of referral for liver transplantation aside from the MELD score?
Is there such a thing as "too early" referral? How can we best utilize the time and resources of a liver transplant center for such patients?
2 Answers available
Given that cardiovascular disease is the top cause of morbidity/mortality in patients with MASLD, do you perform any additional screening and/or testing for these patients to minimize this impact?
1 Answer available
What cardiac testing do you perform for patients undergoing liver transplant evaluation?
1 Answer available
In patients with Met-ALD, how do you approach their treatment plan?
Do you tackle the alcohol first over the metabolic comorbidities? 
1 Answer available
In a patient with Zieve's Syndrome and alcohol related cirrhosis which antibiotic regimen is safe to treat H. pylori?
Most antibiotics used to treat the H. pylori are contraindicated in cirrhosis.
2 Answers available
In patients with Met-ALD, would you still offer the same therapeutic/pharmacologic treatments (ex: GIP/GLP-1 agonists, Resmetirom, ex) for management of their disease as in a "pure" MASLD patient?
1 Answer available
How do you balance infection risk in patients with immune-mediated liver disease on chronic immunosuppression (ex: prednisone, AZA, MMF, etc)?
1 Answer available
What clinical features would raise your suspicion for IgG-4 related disease?
Is a liver mass a presentation of IgG4 related disease?
1 Answer available
For remote liver transplant recipients back under the care of a community gastroenterologist (or PCP), what should be the approach to new liver enzyme elevations?
What should be ordered? Any medications given?
1 Answer available
Do you have any concerns about lower extremity compression (e.g., compression stockings, intermittent pneumatic compression, etc.) worsening ascites in a patient with portal hypertension?
1 Answer available
How do you decide when to initiate or restart diuretics in a cirrhotic patient with ascites if they are receiving a therapeutic paracentesis?
2 Answers available
What graft and patient factors would increase the risk of early graft failure?
What are your management/preventative strategies, and are they specific to your experiences and/or institution?
1 Answer available
Under which circumstances is there a role for reduction in immunosuppression post-SOT in a patient with recurrent CMV viremia and/or disease? 
1 Answer available
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
1 Answer available
How do you balance the need for diuretics from a volume perspective (Ex: ascites, edema) in decompensated cirrhotic patients and progressive renal dysfunction?
Do you opt for "accepting" a higher creatinine and worsening renal dysfunction for more euvolemia? How would this change your practice if a patient wa...
1 Answer available
In what clinical scenario would you consider the use of budesonide over prednisone as part of the pharmacologic management of autoimmune hepatitis?
1 Answer available
In patients with MASLD and F2–F3 fibrosis, would you initiate Resmetirom even if they are not making active lifestyle changes?
And for how long?
3 Answers available
How do you choose between resmetirom and semaglutide in the treatment of MASH?
1 Answer available
When giving albumin challenge, for acute kidney injury with suspected hepatorenal syndrome, do you administer a single dose daily or split the dose of albumin?
1 Answer available
What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?
3 Answers available
In what scenario do you obtain ammonia levels in a patient with cirrhosis?
How would this value impact your subsequent management?
1 Answer available
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
3 Answers available
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
For example, anticoagulation for recent, significant PE or dual antiplatelet therapy for recent MI, but requiring urgent procedures such as biopsy of ...
4 Answers available
Are there any specific guidelines for the transplantation of metastatic disease to the liver or are these institution specific?
In general, for which malignancy would this most commonly be entertained and what patient criteria would make them an optimal candidate?
1 Answer available
Having gone through multiple iterations, what MELD updates/considerations should we anticipate in the future?
1 Answer available
What are your diagnostic and treatment goals for a patient with cirrhotic cardiomyopathy?
Would treating underlying cirrhosis/transplant cure the driver of their cardiac dysfunction, and is this reversible? What unique transplant complicati...
1 Answer available
Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
3 Answers available
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
3 Answers available
Can tamoxifen be safely prescribed for breast cancer patients with cirrhosis?
4 Answers available
How do you foresee the integration of artificial intelligence in the management and evaluation of patients with liver lesions/tumors?
1 Answer available
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
1 Answer available
How do you decide which patient and with which device to pursue machine perfusion for the organ of a liver transplant recipient?
What other patient factors and nuances do you take into consideration in patient selection and use of specific perfusion options (ex: normothermic vs....
2 Answers available
What are some practical tips for when a patient's consistently stated goals of care do not correlate with their actions?
For example, what do you do when someone requests aggressive, life-prolonging treatments but then is not receptive to elements of day-to-day care in t...
4 Answers available
What is your strategy to manage the complication of long-term immunosuppression in liver transplant recipients, specifically renal dysfunction and onset of cardiometabolic comorbidities?
Do you opt for dose reduction? Switching medications?
2 Answers available
What is your strategy to manage peri-procedural bleeding risk in patients with cirrhosis?
Do you use TEG or ROTEM? How do you counsel proceduralists on the unique hemostatic profile of patients with cirrhosis?
1 Answer available
What is your approach to the management of post-TIPS hepatic encephalopathy?
1 Answer available
How would you workup a patient who develops ascites AFTER liver transplantation?
2 Answers available
How do you approach the surveillance and serologic evaluation of a patient in whom you suspect has a hepatitis B pre-core mutant?
What findings would suggest to you that a patient has a pre-core mutant?
1 Answer available
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
1 Answer available
How will the recent withdrawal of Ocaliva for the treatment of PBC impact your therapeutic and management plan for these patients?
1 Answer available
How do you approach the workup for a patient with imaging showing features suggestive of cirrhosis?
2 Answers available
What are your clinical considerations to pursue an automated-low-flow ascites (ALFA) pump for a patient with refractory ascites?
2 Answers available
How do you approach dosing beta blockers for variceal prophylaxis when the standard dose doesn’t achieve the target heart rate?"
1 Answer available
How does the presence of porto-mesenteric vein thrombosis impact a patient's transplant candidacy?
How do you go about working up and managing patients with these findings?
1 Answer available
Is there a serum ammonium level for which you recommend initiation of dialysis in a patient with hepatic encephalopathy?
3 Answers available
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
Patient is undergoing RT and has already started on a GnRH antagonist. If so, how long after their last fraction would be an appropriate wait time?
1 Answer available
How do you decide whether ordering a 5' nucleotidase or a GGT is the most appropriate option in the evaluation of an elevated alkaline phosphatase?
1 Answer available
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
1 Answer available
For how long would you treat a patient with latent TB before allowing them to proceed with a liver transplant?
1 Answer available
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
2 Answers available
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
1 Answer available
With an increase in the prevalence of MASLD in the United States population, what recipient and donor characteristics do you find favorable for acceptance of a highly steatotic graft?
2 Answers available
Who would be the right candidate in which TIPS placement would reduce portal hypertension to allow for a previously unattainable procedure?
(Ex: cholecystectomy, orthopedic surgery, etc.)
2 Answers available
How do you decide whether or not to pursue inpatient workup of an incidental liver mass?
What clinical, system, and/or social factors play into this decision?
1 Answer available
How has the move away from a strict 6 month period of sobriety impacted your patient selection criteria for transplant of patients with alcohol associated liver disease?
1 Answer available
How do you decide whether to use pharmacologic VTE prophylaxis in hospitalized patients with decompensated cirrhosis?
How do factors like the presence of varices, severity of coagulopathy, etc., play into your decision?
2 Answers available
What role do you see for albumin infusions in patients with hypoalbuminemia to help assist in volume status, outside of its use in replenishment after a large volume paracentesis or renal dysfunction?
1 Answer available
How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?
1 Answer available
When would you plan to biopsy a hepatic adenoma to see if it has high risk features/mutations?
1 Answer available
What patient factors impact your selection of initial therapies in patients with localized cholangiocarcinoma?
1 Answer available
How do you determine when you would treat an identified spleno-renal shunt and how?
2 Answers available
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
1 Answer available
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?
Do you perform any subsequent testing?
1 Answer available
What would be the right patient profile and experience for someone who may have (operational) tolerance and how do you approach immunosuppresison management (or withdrawal) in this patient?
1 Answer available
What clinical scenario do you consider screening for hepatitis delta?
1 Answer available
At what BMI or waist-circumference threshold do you opt to move from Fibroscan to other NILDA for fibrosis assessment?
And what would be your choice?
1 Answer available
In what clinical scenario would larsucosterol be considered as therapy in alcohol related hepatitis?
1 Answer available
What is your strategy in the management of patients with autoimmune hepatitis who failed azathioprine therapy and what parameters do you monitor with what frequency?
1 Answer available
What is your approach to perioperative risk stratification and optimization in patients with cirrhosis?
Do you find risk scores such as VOCAL-Penn to be helpful?
1 Answer available
Can tacrolimus in a transplant patient be used during radiation and concurrent chemoradiation?
Does your practice differ depending on the disease site?
1 Answer available
How would you differentiate neurologic manifestations of a patient with Wilson's disease versus manifestations of hepatic encephalopathy due to end-stage liver disease?
1 Answer available
How do you balance infection risk versus therapeutic benefit of steroid tapers when treating patients with alcohol related hepatitis?
1 Answer available
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
1 Answer available
What is your endoscopic approach to the management of refractory GAVE in persistently anemic patients?
1 Answer available
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
1 Answer available
How do you determine which patients are good candidates to have their organ receive machine perfusion therapy before implantation?
1 Answer available
In what scenario do you screen patients with hepatitis B for hepatitis D co-infection?
1 Answer available
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
1 Answer available
When do you pursue liver biopsy for assessment of DILI?
1 Answer available
How do you utilize liver assistive devices in the management algorithm of patients with acute liver failure?
1 Answer available
How do you approach HCC screening in patients with advanced fibrosis e.g., F3 on FibroScan?
1 Answer available
What is your approach to a situation where DILI is suspected secondary to an important medication (e.g., anticoagulation, antibiotics, etc.), but the diagnosis is uncertain and the liver injury is relatively mild?
Are there situations in which you would continue the possible offending agent with close monitoring?
1 Answer available
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequen...
2 Answers available
Do you recommend starting naltrexone at discharge for alcohol use disorder in patients with decompensated cirrhosis secondary to alcohol use?
2 Answers available
Do you avoid terlipressin for patients with hepatorenal syndrome who have an elevated bilirubin level?
2 Answers available
When would you choose to measure a patient's spleen stiffness?
What are you looking for that would impact your management of a patient?
3 Answers available
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
5 Answers available
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
Data are scattered, with some starting concurrent and some starting after SBRT to optimize the priming of the immune system with RT.
1 Answer available
How would you manage a patient with well-controlled HIV on Biktarvy, who is interested in switching to injectable HAART but also has a history of a prior Hepatitis B Infection?
2 Answers available
What variables do you weigh most heavily when choosing which copper chelation therapy you'll recommend for a patient?
1 Answer available
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
1 Answer available
How would you approach the management of drug-induced autoimmune hepatitis compared to non-drug-induced autoimmune hepatitis?
1 Answer available
How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?
1 Answer available
How do you approach fertility/family planning and counseling in patients with end-stage liver disease?
1 Answer available
What is your approach to induction therapy and maintenance therapy for patients with autoimmune hepatitis?
1 Answer available
How do you approach the use of viscoelastic assays (ex: TEG, ROTEM) in patients with identified coagulopathy in the peri-procedural period?
1 Answer available
How do you utilize the Sustained Alcohol Use Post-Liver Transplant (SALT) score on surveillance for alcohol use for patients after liver transplant?
1 Answer available
What is your evaluation approach for a new patient referral for an incidentally found liver lesion?
1 Answer available
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
1 Answer available
What patient features would favor the creation of a Hutson loop intra-operatively?
1 Answer available
What parameters would you use to monitor and interpret iron levels in a hemochromatosis patient where ferritin is unreliable due to underlying chronic inflammation?
How would your recommendation change if the patient has H63 homozygous mutation?
2 Answers available
Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?
2 Answers available
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
2 Answers available
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
1 Answer available
What pre-transplant patient factors impact surveillance intervals and methods after liver transplant for HCC?
1 Answer available
In Fontan-associated liver disease (FALD), what clinical scenario would lead you to pursue an evaluation for simultaneous liver-heart transplant as opposed to heart alone if there is evidence of fibrosis on a liver biopsy?
1 Answer available
What role is there for the assessment of hepatitis B virus genotype as it pertains to pharmacologic therapy and HCC screening?
1 Answer available
Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?
2 Answers available
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
1 Answer available
How do you approach the evaluation of a living donor liver transplant candidate?
What kind of patient would be an ideal recipient of such an organ?
1 Answer available
What patient clinical factors do you find most impact a patient's "beta-blocker window" and their ability to maintain and tolerate beta-blocker therapy?
1 Answer available
How do you counsel patients on the use of marginal organs and/or high risk donors who are on the liver transplant wait list?
1 Answer available
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
1 Answer available
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
1 Answer available
How do you approach risk of development of PTLD in liver transplant recipients with positive EBV antibodies and/or viral loads?
1 Answer available
What management considerations do you keep in mind in the management of pregnant patients with autoimmune liver disease?
1 Answer available
Would you consider long term avatrombopag use in patients with cirrhosis requiring higher platelet counts for medical therapy?
For example, someone needing a higher platelet count for dual antiplatelet agent use after coronary stent placement.
1 Answer available
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
1 Answer available
What clinical evidence do you find most favorable of a positive response post-liver transplant for patients with portopulmonary hypertension?
1 Answer available
Would you ever consider using durvalumab/tremelimumab in second line after progression on atezolizumab and bevacizumab in advanced HCC?
3 Answers available
How do you rule out spontaneous bacterial peritonitis in a patient with minimal ascites that is not amenable to paracentesis?
1 Answer available
How do you manage oxaliplatin-induced splenomegaly?
1 Answer available
What clinical scenario would you favor NOT using terlipressin for the management of HRS if there were no notable contraindications for its initiation?
1 Answer available
How do you manage fatty liver disease in patients on olanzapine who are reluctant to change meds?
I have several forensic patients who have elevated LFTs and fatty liver on ultrasound, at least in part due to long-term olanzapine use. They are all ...
2 Answers available
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
Any management considerations with respect to disease etiology?
1 Answer available
How much do you factor in a patient's frailty in selection for transplant if the underlying driver for their debility is their underlying liver disease itself?
1 Answer available
How do you approach a patient who has incidentally found liver and renal cysts?
1 Answer available
Do you find there is any benefit to giving N-acetyl-cysteine in non-acetaminophen related acute liver failure?
1 Answer available
When would you decide to pursue plasma exchange in a patient in acute liver failure due to sinusoidal obstruction syndrome?
1 Answer available
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
1 Answer available
How long do you treat uncomplicated gram-negative rod bacteremia in solid organ transplant recipients?
1 Answer available
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
2 Answers available
What is your approach to managing concurrent severe SIADH and large-volume malignant ascites when aggressive volume removal appears to exacerbate both symptoms and hyponatremia?
For example, would you consider alternatives to paracentesis (Denver shunt placement, CART therapy, or permanent tunneled catheters) that might better...
1 Answer available
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
2 Answers available
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"
4 Answers available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
What is your preferred dosing of IV ganciclovir for CMV disease in immunocompromised patients?
1 Answer available
How do you approach cognitive impairment in the assessment of transplant candidacy?
1 Answer available


Papers discussed in this category

The New England journal of medicine, 1987-03-05
Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV.
Hepatology (Baltimore, Md.), 2018 Apr
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Dec 31
Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis.
Journal of viral hepatitis, 2019 Dec 22
Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.
Topics in antiviral medicine, 2023 Mar 31
Chronic hepatitis B and HIV coinfection.
Journal of acquired immune deficiency syndromes (1999), 2023 Oct 01
Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Mar 19
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Hepatology (Baltimore, Md.), 2023 May 22
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology, 2025 Jan 15
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.
Investigational new drugs, 2024 Aug 30
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Lancet (London, England), 2015-03-14
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
The New England journal of medicine, 2020 Nov 13
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Gastroenterology, 2015 Apr 10
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
The New England journal of medicine, 2010 Apr 28
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.), 2022 Jan 24
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021 Jun 04
The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.
The New England journal of medicine, 2024 Feb 08
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Hepatology (Baltimore, Md.), 2024 Oct 18
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020 Oct 23
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.
Clinical journal of the American Society of Nephrology : CJASN, 2023 Oct 17
How We Treat Hyperammonemia in Acute Liver Failure.
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Radiother Oncol, 2017 May
Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma.
Hepatology (Baltimore, Md.), 2012 Apr
Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
The New England journal of medicine, 2021 Mar 04
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Archives of internal medicine, 2006 Feb 13
Screening for hemochromatosis in asymptomatic subjects with or without a family history.
Cancer chemotherapy and pharmacology, 2019 Aug 23
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Hepatology (Baltimore, Md.), 2022 Dec 07
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
The American journal of gastroenterology, 2024 Jan 26
ACG Clinical Guideline: Focal Liver Lesions.
The American journal of gastroenterology, 2024 Oct 21
Focal Liver Lesions.
Gastroenterology, 2009-09
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
European journal of endocrinology, 2023 Aug 02
Effect of protein supplementation on plasma sodium levels in the syndrome of inappropriate antidiuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study.
JAMA oncology, 2017-04-01
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018-05
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Transplant international : official journal of the European Society for Organ Transplantation, 2021 Nov 22
The RETREAT score provides valid predictions regarding hepatocellular carcinoma recurrence after liver transplantation.
Cardiovascular and interventional radiology, 2024 Jun 10
Percutaneous Biliary Interventions via the Modified Hutson Loop in Patients with Biliary-Enteric Anastomoses: A Retrospective Study.
Drug and alcohol dependence, 2024 Sep 07
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
JAMA psychiatry, 2025 Apr 01
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Gastroenterology, 2018 May 17
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
The New England journal of medicine, 2012 Aug 23
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Medicine, 2016 Jan
Peritoneal Dialysis is Associated With A Better Survival in Cirrhotic Patients With Chronic Kidney Disease.
Clinical nephrology, 2011 Oct
Outcome of peritoneal dialysis in cirrhotic patients with end-stage renal disease: a 24-years' experience in Taiwan.
The American journal of medicine, 1992 Jul
Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002 Jul
Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure.
The New England journal of medicine, 2024 Jul 25
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-05-20
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
Hepatology (Baltimore, Md.), 2023 Oct 23
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
The New England journal of medicine, 2021 Mar 04
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
Gastroenterology, 2025 Feb
AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.
Lancet Haematol, 2018 Oct
Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.
JHEP reports : innovation in hepatology, 2024 Apr 10
Safety of naltrexone in patients with cirrhosis.
Hepatology (Baltimore, Md.), 2012-01
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients.
Clinical and translational gastroenterology, 2019 Apr
Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
Journal of thrombosis and haemostasis : JTH, 2010 Nov
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.
Journal of thrombosis and haemostasis : JTH, 2022 Aug 10
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH.
Techniques in vascular and interventional radiology, 2016-03
Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022 Jun 16
Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2025 Aug 22
AASLD AST Practice Guideline on Adult Liver Transplantation: Diagnosis and management of Graft-Related complications.
Hepatology (Baltimore, Md.), 2021 Jan 20
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.